Illustration of Insperity as a turnaround stock, featuring a struggling office with payroll and benefits cost stress on one side and a confident executive reviewing HR recovery plans and improving charts on the other

🚀 Insperity (NSP): Why the CEO Just Bought Another $7.9M of This HR Stock

Insperity (NYSE: NSP) continues attracting major insider buying. CEO Paul Sarvadi has now purchased roughly $15.5 million of stock in less than three months, including a new $7.9 million purchase after shares rallied nearly 50%.


Read entire article

A humorous, cinematic cruise ship sailing through choppy Wall Street waters. On deck, a private-equity titan in a blazer holds a giant $25 million boarding pass, a fast-food executive captain wears a Burger King/Subway-style crown-and-captain hat

🚢 Norwegian Cruise Line (NCLH): Why Insiders Just Bought $27M of Stock

Norwegian Cruise Line Holdings may be more than a cruise recovery stock. With a new CEO, nearly $27 million in insider purchases, institutional ownership locking up almost the entire float, and valuation metrics that look surprisingly cheap, NCLH is turning into one of the more intriguing turnaround stories on deck.

Read entire article

A futuristic city powered by artificial intelligence, with glowing data highways connecting global enterprises. A tollbooth labeled

🌐 Globant (GLOB): The AI Infrastructure Tollbooth Trading at 7x Earnings

Globant (NYSE: GLOB) may be one of the most intriguing AI-related value plays on the market. Trading 87% below its peak, the company combines a growing AI-native services platform, accelerating cash flow, aggressive share buybacks, institutional ownership above 100% of float, and a historic first insider purchase from former Hong Kong Exchange CEO Alejandro Aguzin. Is Wall Street missing the story?

 

Read entire article

A biotech laboratory where scientists examine glowing neurons and retinal cells while investors, institutional funds, and short sellers watch a countdown clock labeled

🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough

Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.

Read entire article

Cartoon-style illustration of a confident goose in a business suit representing Goosehead Insurance, standing in a digital insurance command center with AI robots, insurance policies, storm clouds, Wall Street institutions, and worried short sellers.

🪶 Goosehead Insurance (GSHD): The C-Suite Double-Down on a Deeply Plucked Stock

Goosehead Insurance has been deeply plucked, but insiders are buying the dip while Q1 adjusted EBITDA surged 57%. With a tech-enabled, asset-light broker model, institutional ownership above the float, and short interest near 8%, GSHD offers a risky but fascinating GARP setup.

Read entire article

Illustration of a digital tollbooth standing on the Information Superhighway. Businesses, schools, and government agencies drive cloud servers, laptops, and AI robots through the toll plaza while CDW operators collect technology tolls.

🖥️ CDW Corporation (CDW): The Tech Infrastructure Tollbooth Trading at an Uncharacteristic Discount

CDW Corporation may not build AI chips, but it helps organizations deploy the technology revolution. With insider buying, strong earnings, a growing buyback program, and a forward P/E of just 11.2x, this tech infrastructure giant could be trading at one of its most attractive valuations in years.

Read entire article

Illustration of futuristic Celsius energy drink cans glowing with electric neon colors inside a high-performance trading floor and fitness environment hybrid, surrounded by rising stock charts, athletes, institutional investors, and explosive energy waves

⚡ Celsius Holdings (CELH): Wall Street Panicked. Insiders Bought the Dip

Celsius Holdings (CELH) may no longer be just a trendy fitness energy drink brand. With explosive 138% revenue growth, synchronized insider buying, Alani Nu integration success, and PepsiCo’s distribution engine accelerating expansion, the stock increasingly looks like a high-growth GARP opportunity hiding beneath a brutal valuation reset.

Read entire article

Illustration of a massive luxury cruise ship navigating turbulent financial seas at sunset, with glowing stock charts emerging from ocean waves and dramatic storm clouds parting to reveal potential recovery for Norwegian Cruise Line Holdings.

🚢 Norwegian Cruise Line (NCLH): Wall Street Sees Turbulence. Insiders See Opportunity

Norwegian Cruise Line (NCLH) may be one of the market’s most misunderstood recovery plays. Despite heavy debt concerns and softer guidance, insiders are buying aggressively, institutions still dominate ownership, and the stock trades at surprisingly cheap valuation levels relative to long-term earnings potential.

Read entire article

Cartoon-style image of Flutter Entertainment as a giant Wall Street casino, with executives placing huge bets on FLUT stock while poker chips, sportsbook screens, and institutional investors dominate the scene.

🎲 Flutter Entertainment (FLUT): Betting on the House at a 12x Discount

Flutter Entertainment (FLUT) has collapsed 69% from its highs, yet insiders are aggressively buying shares while FanDuel continues dominating U.S. sports betting. Is Wall Street underpricing one of the world’s most powerful gambling platforms?

Read entire article

Cinematic illustration of Boston Scientific as a futuristic medtech powerhouse, with glowing cardiovascular devices, a heart-shaped stock chart, doctors, investors, and a $2B buyback shield symbolizing healthcare innovation and a GARP stock opportunity.

🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse

Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.

Read entire article